RxDoctor Payments Data

Keith Wickenhauser, MD

Internal Medicine · Saint Charles, MONPI 1184042855

Payments from drug & device makers

$11,449in general payments, 2019–2025

Across 841 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Amgen$821
  • AstraZeneca$793
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,32599%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)128$1,614
GSK111$1,195
Pfizer107$1,068
Novo Nordisk78$1,052
Amgen55$821
AstraZeneca43$793
Boehringer Ingelheim28$421
Novartis27$402
Abbott22$306
E.r. Squibb & Sons, L.L.C.15$227
Supernus Pharmaceuticals, Inc.11$221
Lundbeck LLC11$215
Lilly USA, LLC15$213
Johnson & Johnson(2 entities)14$190
Biohaven Pharmaceutical Holding Company Ltd.18$168
Amarin Pharma, Inc.12$161
Antares Pharma, Inc.10$155
Axsome Therapeutics, Inc.8$152
Astellas Pharma US Inc4$152
Merck7$131
Takeda Pharmaceuticals U.S.A., Inc.11$129
Mylan Specialty L.p.7$112
Teva Pharmaceuticals USA, Inc.7$110
Esperion Therapeutics, Inc.6$98
Bayer7$97
Sunovion Pharmaceuticals Inc.6$93
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$70
Otsuka America Pharmaceutical, Inc.5$68
Eisai Inc.4$66
Nevro Corp.3$62
Neotract Inc.1$60
Sumitomo Pharma America, Inc.4$60
Ironshore Pharmaceuticals Inc.4$58
Sanofi-aventis U.S. LLC4$56
Radius Health, Inc.3$51
Exact Sciences3$42
Averitas Pharma Inc.2$39
Kowa Pharmaceuticals America, Inc.3$38
Phathom Pharmaceuticals, Inc.2$35
Biohaven Pharmaceuticals, Inc.2$35
Genentech USA, Inc.2$34
Halozyme Inc2$31
Nestle Healthcare Nutrition Inc.2$31
Shire North American Group Inc2$30
Therapeuticsmd, Inc.2$29
Sanofi Pasteur Inc.2$27
Adlon Therapeutics L.p.2$24
Almatica Pharma LLC1$22
VBI Vaccine (delaware) Inc.1$20
Inspire Medical Systems, Inc.1$17
Optinose US, Inc.1$15
Aytu Biopharma, Inc.1$14
Azurity Pharmaceuticals, Inc.1$14
Regeneron Healthcare Solutions, Inc.1$14
Mylan Pharmaceuticals Inc.1$14
Hikma Pharmaceuticals USA1$14
UCB, Inc.1$13
Idorsia Pharmaceuticals US Inc1$13
Impel Pharmaceuticals Inc.1$13
Vertical Pharmaceuticals, LLC1$12

How this compares

$11,449 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$324,801
Medicare patients
615
Services billed
8,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$414,071
OzempicSemaglutide156$232,088
JardianceEmpagliflozin197$231,908
JanuviaSitagliptin Phosphate103$86,241
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$79,586
MounjaroTirzepatide68$72,738
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr92$61,848
TrulicityDulaglutide34$48,725
MyrbetriqMirabegron79$46,344
FarxigaDapagliflozin Propanediol31$39,192
ArexvyRsvpref3 Antigen/As01e/Pf147$39,069
XareltoRivaroxaban37$37,953
RybelsusSemaglutide27$37,541
RexultiBrexpiprazole27$35,490
GemtesaVibegron17$20,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Paxlovid, Abrysvo$1,068$441,545521 claims
Novo NordiskOzempic, Rybelsus$1,052$269,628183 claims
Boehringer IngelheimJardiance$421$231,908197 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta$1,195$199,591368 claims
Lilly USA, LLCMounjaro, Trulicity$213$121,463102 claims
MerckJanuvia$131$86,241103 claims
AstraZenecaFarxiga, Brilinta, Symbicort$793$57,42363 claims
Astellas Pharma US IncMyrbetriq$152$46,34479 claims
Johnson & JohnsonXarelto$190$37,95337 claims
Otsuka America Pharmaceutical, Inc.Rexulti$68$35,49027 claims
Sumitomo Pharma America, Inc.Gemtesa$60$20,87717 claims
NovartisEntresto$402$10,45515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Charles

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →